Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Lymphomas, Non-Hodgkin lymphoma, Translational Research, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Health outcomes research, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies, Aggressive lymphoma, Immunotherapy, Real-world evidence, Lymphoid Malignancies, Adverse Events, Infusion, Technology and Procedures, Natural Killer (NK) Cell Therapies, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Lymphomas, Non-Hodgkin lymphoma, Translational Research, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Health outcomes research, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies, Aggressive lymphoma, Immunotherapy, Real-world evidence, Lymphoid Malignancies, Adverse Events, Infusion, Technology and Procedures, Natural Killer (NK) Cell Therapies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Marriott Grand Ballroom 11-13
(Marriott Marquis San Diego Marina)
Moderators:
Chenyu Lin, MD, Duke University School of Medicine
and
Kathryn Cappell, National Cancer Institute
Disclosures:
Lin: Autolus: Consultancy; Rigel: Consultancy; ADC Therapeutics: Consultancy.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH